Written and maintained by CASRAI Editorial Board
Last updated
The Biopharmaceutics Classification System (BCS) sorts oral drug substances into four classes using two measured properties — aqueous solubility and intestinal permeability — and uses that classification to predict how reliably a drug’s dissolution rate in vitro will track its absorption in vivo. Originally proposed by Amidon, Lennernäs, Shah, and Crouch in 1995, the framework has since become the scientific basis for one of FDA’s and ICH’s most consequential regulatory shortcuts: the ANDA biowaiver, which lets a generic sponsor substitute an in vitro dissolution comparison for a full comparative pharmacokinetic bioequivalence study for certain drug classes. For anyone scoping a generic submission, an IND-stage formulation program, or the CMC package behind either, knowing which BCS class a compound falls into determines whether a bioequivalence study is a budget line item at all.
The two axes: solubility and permeability
BCS classification rests on two independently measured, continuous properties that regulators convert into binary “high/low” calls using fixed criteria.
Solubility
A drug is classified as highly soluble when its highest single labeled dose strength dissolves completely in 250 mL or less of aqueous media across the physiological pH range the drug will encounter in the GI tract. Under the ICH M9 guideline, that range is tested at pH 1.2, 4.5, and 6.8 — the same three pH points used later for the dissolution comparison in a biowaiver submission. A drug that needs a larger volume, or that is soluble at some of those pH points but not others, is classified as low solubility.
Permeability
A drug is classified as highly permeable when the extent of intestinal absorption (or documented complete metabolic/systemic stability that makes absorption a non-issue) is high enough that permeability is not expected to limit how much of the dose reaches systemic circulation. Regulatory permeability determinations are typically benchmarked against a reference compound with well-characterized human absorption data. A drug that falls short of that benchmark is classified as low permeability, regardless of how quickly it dissolves.
The four BCS classes and what each means for formulation
| Class | Solubility | Permeability | What it means for an oral IR product |
|---|---|---|---|
| Class 1 | High | High | Dissolution and permeability are both favorable; absorption is generally rapid, complete, and predictable across simple formulations. |
| Class 2 | Low | High | Absorption is dissolution-rate-limited; formulators lean on particle-size reduction, salt selection, solid dispersions, or lipid-based delivery to get enough drug into solution. |
| Class 3 | High | Low | The drug dissolves readily but crossing the gut wall is the bottleneck; absorption can be sensitive to permeation-affecting excipients and GI transit time. |
| Class 4 | Low | Low | Both dissolution and permeability limit absorption; oral immediate-release bioavailability is often poor and erratic, and formulators frequently need advanced delivery technology or a non-oral route. |
The practical value of the classification is predictive: Class 1 compounds tend to give a formulator few surprises, because neither axis is a bottleneck, so in vitro dissolution data are a genuinely reliable proxy for in vivo performance. Class 2 and Class 3 compounds each have one favorable and one unfavorable property, which is where most of pharmaceutics’ formulation-science effort concentrates — different tools depending on which axis is the problem. Class 4 compounds are the hardest oral development candidates on the map; a meaningful share never reach an immediate-release oral product at all.
The BCS-based biowaiver: when in vivo bioequivalence testing can be skipped
A standard generic drug approval under an ANDA normally requires an in vivo bioequivalence study: dosing the test and reference products in healthy volunteers and comparing plasma concentration-time profiles (the 80.00%–125.00% 90% confidence interval rule covered in CASRAI’s PBPK modeling content applies here). The BCS-based biowaiver, formalized internationally in ICH M9 (Biopharmaceutics Classification System-Based Biowaivers), adopted at Step 4 in November 2019, and implemented domestically through FDA guidance, allows a sponsor to substitute comparative in vitro dissolution testing for that clinical study — but only for immediate-release solid oral dosage forms, and only within specific class and formulation boundaries. That comparative dissolution-versus-bioequivalence question sits inside the broader ANDA approval framework at 21 CFR Part 314, and a post-approval formulation or excipient change substantial enough to reopen it is the kind of change tracked under 21 CFR 314.70.
Class 1: the primary biowaiver candidate
Class 1 drugs are the framework’s main target. To qualify, a sponsor must generally demonstrate:
- Rapid, similar in vitro dissolution of the test and reference product across pH 1.2, 4.5, and 6.8 (evaluated using the f2 similarity factor comparison standard in dissolution testing).
- Excipients that are either qualitatively and quantitatively the same as the reference product, or well-precedented compendial excipients not expected to affect GI absorption or motility.
- The drug is not a narrow therapeutic index compound, and is not intended for absorption in the oral cavity — both are excluded from BCS biowaivers regardless of class.
Class 3: a conditional allowance, not a default
ICH M9 also permits a biowaiver for Class 3 drugs, but on materially stricter terms than Class 1. Because permeability, not dissolution, is the bottleneck for a Class 3 compound, the guideline requires evidence that permeability is not the rate-limiting step for absorption, plus very rapid and closely matched dissolution of test and reference across all three pH conditions, and a formulation that is essentially identical in its excipients to the reference product — the excipient tolerance that applies to Class 1 does not carry over, because a permeability-limited drug is far more sensitive to formulation changes that affect GI transit or local permeability than a drug where dissolution was already the limiting step.
Classes 2 and 4: excluded
Class 2 and Class 4 drugs are not eligible for a BCS-based biowaiver. For Class 2, low solubility means in vitro dissolution data cannot reliably bridge to in vivo absorption the way it can for a highly soluble drug — formulation differences that look equivalent in a dissolution vessel can still produce meaningfully different exposure in patients. Class 4 compounds carry that same problem on top of a permeability limitation, so an in vivo comparative PK study remains the regulatory expectation for both classes.
Why this matters for planning a regulatory or clinical program
For a sponsor or CRO scoping a generic drug development program, BCS classification is a go/no-go input on study design long before a protocol is written: a well-characterized Class 1 compound with a straightforward IR formulation can, in principle, reach an ANDA submission without ever dosing a human volunteer for bioequivalence purposes, while a Class 2 or 4 compound is committed to the cost, timeline, and IRB/regulatory oversight of a full in vivo study from the outset. That distinction affects budget forecasting, clinical operations staffing, and how early formulation scientists need to be looped in on the regulatory strategy — a compound initially assumed to be a biowaiver candidate that turns out, on solubility or permeability testing, to sit in Class 2 or 3 can force a late and expensive pivot to an in vivo study. Getting the classification right, and confirming it against current FDA and ICH M9 criteria rather than an outdated internal assumption, is worth doing early rather than discovering it during a pre-ANDA meeting.
Common pitfalls
- Treating “soluble enough to dissolve in the lab” as “BCS-high-solubility.” The regulatory definition is dose-strength-specific and tested across three pH points, not a single generic solubility figure from an early-development assay.
- Assuming Class 3 biowaivers work like Class 1 ones. The excipient-similarity bar is stricter, and the dissolution requirement is more demanding — a formulation change that would be fine for a Class 1 biowaiver can disqualify a Class 3 one.
- Overlooking the narrow-therapeutic-index and oral-cavity-absorption exclusions. These apply regardless of class and are an easy thing to miss when a compound otherwise looks like a clean Class 1 candidate.
- Classifying a modified-release product under the immediate-release biowaiver pathway. The BCS-based biowaiver framework in ICH M9 applies to immediate-release solid oral dosage forms; extended- or delayed-release products are evaluated differently.
Frequently asked questions
What is the Biopharmaceutics Classification System?
It is a scientific framework, first proposed in 1995, that classifies orally administered drug substances into four classes based on aqueous solubility and intestinal permeability, and uses that classification to predict how reliably in vitro dissolution testing tracks in vivo absorption.
What makes a drug “high solubility” under BCS?
Its highest labeled dose strength must dissolve completely in 250 mL or less of aqueous media across the physiological pH range tested (pH 1.2, 4.5, and 6.8 under ICH M9).
Which BCS class is eligible for a biowaiver?
Class 1 is the primary eligible class. Class 3 is conditionally eligible under stricter dissolution and excipient-similarity requirements. Class 2 and Class 4 are not eligible for a BCS-based biowaiver.
Can a BCS Class 3 drug always get a biowaiver?
No. It requires very rapid, closely matched dissolution of test and reference products, evidence that permeability is not rate-limiting, and a formulation that is essentially identical to the reference product in its excipients — a materially higher bar than Class 1.
Are narrow therapeutic index drugs eligible for a BCS biowaiver?
No. Narrow therapeutic index drugs are excluded from BCS-based biowaivers regardless of which class they fall into, because the clinical consequences of even a small bioequivalence miss are too high to rely on an in vitro proxy.
Does the BCS biowaiver pathway apply to extended-release products?
No. The ICH M9 BCS-based biowaiver framework applies to immediate-release solid oral dosage forms. Modified-release products are assessed under separate criteria.
